Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in a patient with erythrodermic psoriasis

被引：9

作者：

Bakri, Faris G.

Abu Al-Hommos, Nisreen

Shehabi, Asem

Naffa, Randa G.

Cui, Longzhu

Hiramatsu, Keiich

机构：

[1] Jordan Univ Hosp, Dept Med, Div Infect Dis, Amman 11942, Jordan

[2] Univ Jordan, Fac Med, Dept Pathol Microbiol, Amman, Jordan

[3] Juntendo Univ, Dept Bacteriol, Tokyo, Japan

来源：

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES | 2007年 / 39卷 / 05期

关键词：

D O I：

10.1080/00365540601105780

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

A 49-y-old male with erythrodermic psoriasis developed persistent bacteraemia for 3 months due to methicillin-resistant Staphylococcus aureus despite antimicrobial therapy. The skin was the likely focus. Three consecutive isolates from the blood and 1 from the nose were identical and had vancomycin MIC of 4 mg/l.

引用

收藏

页码：457 / 460

页数：4

相关论文

共 14 条

[1] Combination effect of vancomycin and β-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin [J].

Aritaka, N ;

Hanaki, H ;

Cui, LZ ;

Hiramatsu, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1292-1294

[2] Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus [J].

Charles, PGP ;

Ward, PB ;

Johnson, PDR ;

Howden, BP ;

Grayson, ML .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :448-451

[3]

CLSI, 2006, PERF STAND ANT SUSC

[4]

Fowler VG, 2004, J INFECT DIS, V190, P1140, DOI 10.1086/423145

[5] Infectious complications of erythrodermic psoriasis [J].

Green, MS ;

Prystowsky, JH ;

Cohen, SR ;

Cohen, JI ;

Lebwohl, MG .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (05) :911-914

[6]

Haraga Isao, 2002, International Journal of Infectious Diseases, V6, P302, DOI 10.1016/S1201-9712(02)90165-7

[7] Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin [J].

Hiramatsu, K ;

Aritaka, N ;

Hanaki, H ;

Kawasaki, S ;

Hosoda, Y ;

Hori, S ;

Fukuchi, Y ;

Kobayashi, I .

LANCET, 1997, 350 (9092) :1670-1673

[8] Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA) [J].

Howden, BP .

INTERNAL MEDICINE JOURNAL, 2005, 35 :S136-S140

[9] Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility [J].

Howden, BP ;

Ward, PB ;

Charles, PGP ;

Korman, TM ;

Fuller, A ;

du Cros, P ;

Grabsch, EA ;

Roberts, SA ;

Robson, J ;

Read, K ;

Bak, N ;

Hurley, J ;

Johnson, PDR ;

Morris, AJ ;

Mayall, BC ;

Grayson, ML .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (04) :521-528

[10] Microbiological features of vancomycin in the 21st century: Minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains [J].

Jones, RN .

CLINICAL INFECTIOUS DISEASES, 2006, 42 :S13-S24